

School of Biomedical Science**Master of Science Clinical Research
Semester End Examination - Jun 2024****Duration : 180 Minutes
Max Marks : 100****Sem II - Q1PK207B - Drug Discovery and Development**General Instructions*Answer to the specific question asked**Draw neat, labelled diagrams wherever necessary**Approved data hand books are allowed subject to verification by the Invigilator*

- | | | |
|-----|--|--------|
| 1) | Define the IMRDA-Composition. | K1(2) |
| 2) | Explain QSEM in ICH. | K2(4) |
| 3) | Explain the Phase 2 Clinical trial in clinical research. | K2(6) |
| 4) | Illustrate the IND review process in clinical research. | K3(9) |
| 5) | Illustrate the the steps involved in new drug discovery. | K3(9) |
| 6) | Examine the Follow-up Studies for Safety Pharmacology Core Battery in S7A. | K5(10) |
| 7) | Analyze the new drug application process. | K4(12) |
| 8) | Examine the guide lines of (E2A) in Clinical Safety Studies. | K5(15) |
| 9) | Examine the guide lines of (S7A) in Preclinical evaluation. | K5(15) |
| 10) | Elaborate the Sponsor responsibilities for maintaining the integrity clinical research data. | K6(18) |